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Wilkins.Hypertension is the most common cardiovascular disorder
and atrial fibrillation is the most common clinically
significant arrhythmia. Both these conditions frequently
coexist and their prevalence increases rapidly with aging.
There are different risk factors and clinical conditions
predisposing to the development of atrial fibrillation, but
due its high prevalence, hypertension is still the main risk
factor for the development of atrial fibrillation. Several
pathophysiologic mechanisms (such as structural changes,
neurohormonal activation, fibrosis, atherosclerosis, etc.)
have been advocated to explain the onset of atrial
fibrillation. The presence of atrial fibrillation per se
increases the risk of stroke but its coexistence with high
blood pressure leads to an abrupt increase of
cardiovascular complications. Different risk models are
available for the risk stratification and the prevention of
thromboembolism in patients with atrial fibrillation. In all
of them hypertension is present and is an important risk
factor. Antihypertensive treatment may contribute to
reduce this risk, and it seems some classes are superior to
others in the prevention of new-onset atrial fibrillation and
prevention of stroke. Antithrombotic treatment with
warfarin is effective in the prevention of thromboembolic
events, although quite recently, new classes of
anticoagulants that do not require international normalized
ratio monitoring have been introduced with promising
results.
Keywords: anticoagulants, antihypertensive treatment,
atrial fibrillation, hypertension
Abbreviations: ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker; b.i.d., bis in
die (twice a day); CCB, calcium channel blockers; ESC,
European Society of Cardiology; ESH, European Society of
Hypertension; FDA, Federal Drug Association; hs-CRP,
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Journal of HypertensionINTRODUCTIONH
ypertension is the most common cardiovascular
disorder affecting 20–50% of the adult population
in developed countries [1]. The prevalence of
hypertension increases with age, rising steeply after the
age of 50, and affecting more than 50% of this population.
Atrial fibrillation is the most common clinically significant
sustained cardiac arrhythmia, occurring in 1–2% of the
general population. Over 6 million Europeans suffer from
atrial fibrillation, and its prevalence is estimated to at least
double in the next 50 years as the population ages [2].
In recognition of the burden of atrial fibrillation among
hypertensive individuals theWorking Group ‘Hypertension
arrhythmias and thrombosis’ of the European Society of
Hypertension (ESH), decided to write a position paper on
the diagnostic approach, prevention and treatment oforized reproduction of this article is prohibited.
DOI:10.1097/HJH.0b013e32834f03bf
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view to summarize ‘best practice’.
The present document summarizes the available evi-
dence, and puts forward consensus statements that may
help to define evidence gaps and assists in everyday clinical
practice. The ultimate judgement regarding care of a
particular patient must be made by the healthcare provider
in light of all of the circumstances presented by the patient.
EPIDEMIOLOGY
Different risk factors, clinical conditions and subclinical or
clinical organ damage such as hypertension, diabetes mel-
litus, obesity, sleep apnoea, age, metabolic syndrome, left
ventricular hypertrophy (LVH), coronary heart disease,
heart failure and the like are important risk factors for
the development of atrial fibrillation (Box 1). Hypertension
per se increases the risk of atrial fibrillation by about two-
fold [3]. However, due to the high prevalence of hyperten-
sion in the population, hypertension accounts for more
cases of atrial fibrillation than any other risk factor. Hyper-
tension commonly coexists with many conditions associ-
ated with atrial fibrillation, namely in 72% of stroke patients,
82% of chronic kidney disease, 77% of diabetics, 73% of
coronary artery disease, 71% of heart failure patients and
62% of metabolic syndrome [4]. Long-standing hyperten-
sion, especially if sub-optimally controlled, leads to LVH,
structural changes and enlargement of the left atrium,
heterogeneity of atrial conduction and fibrosis [5], all of
which may contribute to the development of atrial fibrilla-
tion [6–9].
Hypertension is frequently seen in patients with atrial
fibrillation as those included in major clinical trials. In
particular, it was found in 49–90% of individuals in atrial
fibrillation trials [49% in Pharmacological Intervention in
Atrial Fibrillation, 51% in Atrial Fibrillation Follow-up Inves-
tigation of Rhythm Management (AFFIRM), 51.8% in Can-
desartan in Heart Failure: Assessment of Reduction in
Mortality and Morbidity, 55% in RAte Control Efficacy in
permanent atrial fibrillation, 62.6% in Strategies of Treat-
ment of Atrial Fibrillation, 63% in Heart Survey, 64.4% in
How to Treat Chronic Atrial Fibrillation, 68% in Registry on
Cardiac Rhythm Disorders Assessing the Control of Atrial
Fibrillation, 71% in AFFIRM overall, 86.3% in A Placebo-
Controlled, Double-Blind, Parallel Arm Trial to Assess the
Efficacy of Dronedarone 400mg bid for the Prevention of
Cardiovascular Hospitalization or Death From Any Cause inCopyright © Lippincott Williams & Wilkins. Unaut
Box 1 Epidemiology and consequences of hypertension and atrial fibrillation
1. Hypertension accounts for more cases of atrial fibrillation than any other risk
factor, and has been found to affect up to 90% of the participants in atrial
fibrillation trials.
2. Atrial fibrillation may occur in all stages of cardiovascular continuum, and
the presence of atrial fibrillation at all stages increases the risk of
cardiovascular morbidity and mortality.
3. Consequences of atrial fibrillation include increase in overall mortality,
stroke, heart failure, hospitalization, it affects quality of life and results
in impaired cognitive function.
4. At the very least, the coexistence of hypertension and atrial fibrillation will
double the risk for all of the above.
5. More than 30% of patients have asymptomatic atrial fibrillation but the risk
is the same as in symptomatic ones.
240 www.jhypertension.comPatients With Atrial Fibrillation/Atrial Flutter, 86.6% in Atrial
Fibrillation Clopidogrel Trial with Irbesartan for Prevention
of Vascular Events (ACTIVE), 80% in Randomized Evalu-
ation of Long-Term Anticoagulation Therapy (RELY), 90%
in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonist for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-
AF) and 86% in Apixaban versus Acetylsalicylic Acid to
Prevent Strokes (AVERROES)], showing the significant role
of hypertension in the development of atrial fibrillation
[10–22] (Fig. 1). Hypertension is a risk factor for chronic
kidney disease, and recent studies have shown that the
progression of renal dysfunction is a powerful predictor of
new-onset atrial fibrillation in patients with hypertension,
independently of LVH and left atrial dilatation [23].
Atrial fibrillation may occur in all stages of the cardio-
vascular disease continuum. In the early stages the pres-
ence of multiple risk factors (hypertension, diabetes, and
obesity) predispose patients to atrial fibrillation, but the
development of subclinical and clinical organ damage not
only predisposes patients to atrial fibrillation, but the pres-
ence of atrial fibrillation may in turn increase the risk of
cardiovascular disease (Fig. 2). In a subanalysis from the
Action in Diabetes and Vascular Disease (ADVANCE)
Study (75% were taking antihypertensive treatment), with
4.3 years of follow-up, patients with diabetes and atrial
fibrillation were at 61% increased risk for all-cause mortality
and had similarly higher risks for cardiovascular death,
stroke and heart failure (61%), compared to patients who
did not have atrial fibrillation [24].
Atrial fibrillation is the most common arrhythmia in
patients with heart failure and it worsens prognosis in
New York Heart Association classes III–IV [25]. A recent
meta-analysis with more than 54 000 patients found that
atrial fibrillation was significantly associated with all-cause
mortality [26]. Not only the presence of atrial fibrillation but
also the new onset of atrial fibrillation carries a higher risk in
patients with heart failure. In the Euro Heart Failure Survey
among patients hospitalized for heart failure, the rate of in-
hospital mortality was significantly higher in those patients
with new-onset atrial fibrillation than in those with no atrial
fibrillation or those with prior documented atrial fibrillation
[27]. Atrial fibrillation is the leading cause of hospitalizations
for arrhythmias and accounts for approximately one third of
hospitalizations for heart rhythm disturbances [28]. Indeed,
atrial fibrillation hospitalizations have increased dramatic-
ally in recent years by two to three times [29].
PATHOPHYSIOLOGY
Untreated or suboptimally treated hypertension leads to the
development of LVH, which is one of the most important
expressions of subclinical organ damage, and is an inde-
pendent risk factor for cardiovascular events, including the
development of atrial fibrillation. In the presence of LVH,
left ventricular compliance is reduced, left ventricular stiff-
ness and filling pressure increase, coronary flow reserve is
decreased, wall stress is increased and there is activation of
the sympathetic nervous system and of the renin–angio-
tensin–aldosterone system. In the atria, proliferation and
differentiation of fibroblasts into myofibroblasts andhorized reproduction of this article is prohibited.
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FIGURE 1 Prevalence of hypertension in atrial fibrillation trials.
Hypertension and atrial fibrillationenhanced connective tissue deposition and fibrosis are the
hallmarks of this process. Structural remodelling results in
electrical dissociation between muscle bundles and in local
conduction heterogeneities facilitating the initiation and
perpetuation of atrial fibrillation. This electroanatomical
substrate permits multiple small re-entrant circuits that
can stabilize the arrhythmia. Over time tissue remodelling
promotes and maintains atrial fibrillation by changing the
fundamental properties of the atria. Atrial remodelling
consists of three components:C
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2 Presence of atrial fibrillation in different stages of cardiovascular continuum.
al of Hypertensionintracellular changes in calcium handling lead to a
reduction in the action potential duration. Even in the
case of prolonged atrial fibrillation, electrical remod-
elling reverses quickly and completely once sinus
rhythm is restored.2. Contractile remodelling: occurs rapidly. The abnor-
mal calcium handling at the high rates of contraction
seen in atrial fibrillationmay be responsible for loss of
contractility. The contractile remodelling induced by
atrial fibrillation may be responsible for its most
devastating consequence, which is stroke. Impaired
atrial contraction leading to stasis of blood, primarily
in the left atrial appendage, is thought to be the majord reproduction of this article is prohibited.
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242contributor to the development of blood clots, thus
promoting thromboembolic events.3. Structural tissue remodelling: occurs after periods of
weeks or months and in this case we have macro-
scopic and microscopic changes in the myocardium,
which contribute to contractile dysfunction and
decreased cardiac output [30].In the Framingham Heart Study the levels of SBP and
duration of hypertension were predictive of adverse left
atrial remodelling [31], whereas a wide pulse pressure is
associated with increased incidence of atrial fibrillation [32].
A study of 1665 older individuals reported a 48% higher risk
of atrial fibrillation in those with a 30% increase in left atrial
volume [33]. The monitoring of trends and determinations
in cardiovascular disease/cooperative research in the
region of Augsburg study reported that both obesity and
hypertension were independent predictors of left atrial
enlargement [odds ratio (OR) 2.4 and 2.2, respectively,
P< 0.001], but the coexistence of hypertension with obesity
was associated with higher left atrial enlargement [34]. Both
obesity and hypertension are risk factors for atrial fibrilla-
tion and both have been associated with birth weight [35]. A
recent prospective study of 27 982 women reported a
significant association between birth weight and atrial
fibrillation [36]. According to another study in patients with
hypertension, highly sensitive C-reactive protein (hs-CRP)
and P wave dispersion are interrelated and associated with
atrial fibrillation, suggesting an active role of inflammation
in the atrial electrophysiological remodelling predisposing
to atrial fibrillation [37].CONSEQUENCES OFATRIAL
FIBRILLATION
Atrial fibrillation is an independent risk factor for death.
Compared to individuals with normal sinus rhythm, those
with atrial fibrillation have a 40–90% higher risk of overall
mortality [38]. Atrial fibrillation complicates or is frequently
associated with other cardiovascular disorders, and the two
most important ones are stroke and heart failure (Table 1)
[39–42]. It is well known that hypertension is a major risk
factor for stroke, but many studies have shown that atrial
fibrillation is an independent risk factor for stroke and
thromboembolic events. Atrial fibrillation is responsible
for 15–20% of all ischemic strokes [43], increases the risk
of stroke four-fold to five-fold [42], and is an independentyright © Lippincott Williams & Wilkins. Unaut
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www.jhypertension.comrisk factor for ischemic stroke severity and recurrence [44].
Other consequences of atrial fibrillation include worsening
of cognitive function, increased risk of hospitalization and
cost, and impaired quality of life. In the Losartan Interven-
tion for End Point Reduction in Hypertension (LIFE) study,
for example, patients with new-onset atrial fibrillation had
approximately two-fold increased risk of cardiovascular
events, about three-fold higher risk of fatal and nonfatal
stroke, and five-fold increased rate of hospitalization for
heart failure [9]. In the Valsartan Antihypertensive Long-
term Use Evaluation (VALUE) trial patients with new-onset
atrial fibrillation had equally poor cardiovascular prognosis
at the end of the follow-up period as those with atrial
fibrillation at baseline, and new-onset atrial fibrillation
was present in almost all patients who developed heart
failure whether they had concomitant diabetes or not [45].
In the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial, baseline atrial fibrillation or atrial
flutter also increased cardiac morbidity and mortality [46].
The systematic review from the Stroke Risk in Atrial
Fibrillation Working Group identified the following inde-
pendent risk factors for stroke: prior stroke or transient
ischemic attack, increasing age, history of hypertension,
diabetes mellitus, structural heart disease and obesity [47].
In the presence of both hypertension and atrial fibrillation,
data from the Atrial Fibrillation Investigators have shown
that the risk of stroke doubled (10.4%) in patients with atrial
fibrillation associatedwith hypertension or diabetes or prior
stroke compared to those without these comorbidities
(4.3%). In patients with atrial fibrillation and history of
hypertension there was a three-fold increase in the annual
incidence of stroke compared to those without a history
of hypertension [48]. In at least 33% of atrial fibrillation
patients, the arrhythmia could be asymptomatic [49]. Holter
and transtelephonic monitoring studies have demonstrated
that asymptomatic episodes of paroxysmal atrial fibrillation
are 10–12 times more frequent than symptomatic episodes
[50,51], but the consequences are the same. The Asympto-
matic Stroke and Atrial Fibrillation Evaluation in Pacemaker
Patients Trial followed 2600 patients who were at least
65 years old with history of hypertension but no history
of atrial fibrillation who received a pacemaker or implant-
able cardioverter defibrillator, and found that over 36% had
a device-detected atrial arrhythmia. According to the find-
ings, those who had one episode within the first 3 months
had more than doubled the risk of stroke or systemic
embolism [52]. Paroxysmal atrial fibrillation has a significanthorized reproduction of this article is prohibited.
Atrial fibrillation with comorbidities
HTNd: CV events X 3
Stroke X 3
Hospitalizations for HF X 2
X 2
In-hospital mortality X 2
Long-term mortality X 1.8
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TABLE 2. Risk factors, clinical conditions and markers for the
development of atrial fibrillation
Risk factors Markers
Age Increased arterial stiffness
Hypertension Left atrial enlargement
Diabetes mellitus Increased PR interval
Obesity P wave dispersion
Hypertension and atrial fibrillationimpact on patient quality of life independent of frequency
or duration of symptoms and the impaired quality of life is
similar to that in heart failure, myocardial infarction and
angioplasty [39,53,54]. Recent data from the Intermountain
Heart Collaborative Study showed that atrial fibrillation is
independently associated with all forms of dementia and
with an increased risk for Alzheimer’s disease [55].Metabolic syndrome Birth weight
Alcohol consumption hs-CRP
Smoking Inflammatory markers
Clinical conditions Neurohormones
Left ventricular hypertrophy Genetic variants
Myocardial infarction Pulse pressure
Heart failure
Obstructive sleep apnoea
Renal dysfunction
Valvular heart disease
Thyroid disease
hs-CRP, highly sensitive C-reactive protein.DIAGNOSTIC APPROACH AND RISK
STRATIFICATION FOR ATRIAL
FIBRILLATION
Atrial fibrillation may cause symptoms such as palpitations,
dizziness, anxiety, generalized weakness, and mild short-
ness of breath. However, up to 90% of atrial fibrillation
episodes may be asymptomatic. More serious signs and
symptoms, such as chest pain, severe shortness of breath
and hemodynamic instability, may be due to associated
cardiac disease such as ischemic heart disease or heart
failure. When atrial fibrillation is suspected, a 12-lead
ECG is recommended as first step to establish the diagnosis.
When arrhythmia or therapy related symptoms are sus-
pected, monitoring using Holter recordings or external
event recorders should be considered. In patients with
hypertension an echocardiogram should be considered.
Various cardiac diseases, including ischemic heart disease,
valvular diseases, and heart failure, are associated with
atrial fibrillation. Therefore, after the diagnosis of atrial
fibrillation is confirmed with ECG or other cardiac tests,
an evaluation of serum cardiac biomarkers and B-type
natriuretic peptide should be considered.
However, there is still the need to improve clinicians’
ability to diagnose atrial fibrillation. Data from the Screen-
ing for Atrial Fibrillation in the Elderly (SAFE) study showed
that among general practitioners and nurse practitioners
from 49 practices in Central UK, themajority of primary care
providers were not able to reliably diagnose the presence or
absence of atrial fibrillation on ECG; 20% of cases of atrial
fibrillation were missed and the probability that a diagnosis
of atrial fibrillation was correct only in 41% [56]. Atrial
fibrillation is classified as first diagnosed (irrespective of
the duration), paroxysmal (self-terminating usually within
48 h or in fewer that 7 days), persistent (lasts longer than
7 days or required termination by cardioversion) and per-
manent (exists for more than 1 year). A silent atrial fibrilla-
tion may be discovered from an atrial fibrillation-related
complication as first manifestation or may be diagnosed by
an opportunistic ECG [57]. There are two types of risk: risk
for atrial fibrillation and risk from atrial fibrillation. There
are different risk factors for the development of atrial
fibrillation. The early recognition of the risk factors that
can lead to the development of atrial fibrillationmay help to
develop risk prediction models to direct preventive efforts
especially in asymptomatic atrial fibrillation. Several vari-
ables have been shown to increase the risk for atrial
fibrillation, including clinical conditions, cardiovascular risk
factors and subclinical markers (Table 2). Hypertension
increases the risk for atrial fibrillation in men and women
by 1.5-fold and 1.4-fold, respectively, and is the most
common underlying risk factor for the development ofCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensionatrial fibrillation [3]. Framingham researchers developed a
risk prediction model to determine an individual’s absolute
risk of developing atrial fibrillation within the next 10 years
based on a number of clinical factors identified to be
predictive for atrial fibrillation. By multivariate analyses
age, sex, BMI, SBP, treatment of hypertension, PR interval
and heart failure accounted for up to 64% of the risk [58].
RISK STRATIFICATIONAND
PREVENTIONOF THROMBOEMBOLISM
FROM ATRIAL FIBRILLATION
Atrial fibrillation is associated with an increased risk of
thromboembolism resulting in transient ischemic attack,
stroke or peripheral embolization. A history of stroke or
transient ischemic attack, increasing age, hypertension and
structural heart disease (LVH or dysfunction) were ident-
ified as predictors of stroke in patients with atrial fibrillation.
Numerous risk factors have been used to formulate various
stroke risk stratification schemes and several predictive
rules have been developed to determine the risk of com-
plications from atrial fibrillation. Due to its simplicity and
ease of use, the CHADS2 (Congestive heart failure, Hyper-
tension, Age, Diabetes, Stroke) score has become the most
commonly used predictive rule in clinical practice [59]. The
CHADS2 index assigns 1 point each for a history of heart
failure, hypertension, age more than 75 years and diabetes,
and 2 points for a history of stroke or transient ischemic
attack. Based on their score patients can be classified as
having low risk (score 0), moderate risk (score 1) or
moderate/high risk (score 2 or greater) for stroke. Aspirin
(81–325mg) is recommended for low risk, aspirin or anti-
coagulation (warfarin) for moderate risk and anticoagula-
tion with warfarin for patients with CHADS2 score at least 2,
with an international normalized ratio (INR) of 2.0–3.0
(target 2.5) unless contraindicated. A refined version of
the original CHADS2 score using what was previously
referred to as ‘less well validated or weaker stroke risk
factors’ in the older guidelines, that is, female sex, age 65–
74 years, and vascular disease, and known as the CHA2DS2-
VASc score [60] was recently validated in severalorized reproduction of this article is prohibited.
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Box 2 Atrial fibrillation and antihypertensive treatment
1. Our main goal in patients with hypertension and atrial fibrillation is blood
pressure reduction per se.
2. Drugs blocking the renin–angiotensin–aldosterone system reduce the risk
of new-onset atrial fibrillation. Nevertheless this effect has been mainly
observed in high-risk patients particularly in those with left ventricular
dysfunction, left ventricular hypertrophy and postmyocardial infarction
patients. Most of the supportive data is from posthoc analyses
3. Beta-blockers are effective for rate control and possibly for maintaining
sinus rhythm. There is not enough data regarding their use in the prevention
of new-onset atrial fibrillation.
4. There is not enough data for the other drug classes.
Manolis et al.independent cohorts. The CHA2DS2-VASc score outper-
formed the CHADS2 score in identifying ‘truly low-risk’
individuals who do not need antithrombotic therapy,
whereas those with at least one stroke risk factors should
be considered for oral anticoagulation therapy, whether
this is undertaken with well controlled warfarin or one of
the new agents that do not require INRmonitoring that have
been introduced (see below). Figure 3 shows the CHA2DS2-
VASc score and the relation between these risks scores and
the annual risk of stroke.
MANAGEMENTOFATRIAL
FIBRILLATION
Management of patients with atrial fibrillation is aimed at
preventing atrial fibrillation by controlling the risk factors
for the development of atrial fibrillation, at reducing the
symptoms, and at preventing severe complications associ-
ated with atrial fibrillation. In this position paper we will
discuss the role of antihypertensive and antithrombotic
therapy in patients with atrial fibrillation, but will not
address other topics such as rate and rhythm control,
ablation and so on, because they are covered by the
recently published European Society of Cardiology (ESC)
guidelines for the management of atrial fibrillation [57].
ATRIAL FIBRILLATIONAND
ANTIHYPERTENSIVE TREATMENT
Antihypertensive drugs reduce the risk for atrial fibrillation
mainly by lowering high blood pressure. However, some
antihypertensive drugs may also reduce the risk for atrial
fibrillation through other mechanisms (Box 2). There haveCopyright © Lippincott Williams & Wilkins. Unaut
244 www.jhypertension.combeen few prospective studies on the development of atrial
fibrillation in hypertensive individuals, but there are several
secondary analyses of large randomized trials and some
meta-analyses.
Renin–angiotensin system blockers
(angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers)
In an early meta-analysis of 11 randomized controlled
clinical trials by Healey et al. [61], the authors found that
renin–angiotensin system (RAS) blockers significantly
reduced the relative risk (RR) of new-onset atrial fibrillation
by 28% (15–40%), but this benefit was limited to patients
with systolic left ventricular dysfunction or LVH. In another
meta-analysis by Kalus et al. [62], the use of an angiotensin-
converting enzyme inhibitor (ACEI) or an angiotensin
receptor blocker (ARB) was associated with an average
49% (35–72%) relative reduction in new-onset atrial fibril-
lation, a 53% (24–92%) lower failure rate of electrical
cardioversion of atrial fibrillation, and a 61% (20–75%)horized reproduction of this article is prohibited.
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Hypertension and atrial fibrillationlower rate of recurrence of atrial fibrillation after electrical
cardioversion. In a meta-analysis by Schneider et al. [63],
RAS-blockade reduced the OR for atrial fibrillation by 32%
(0.22–0.43, P< 0.00001), with similar effects of ACEIs and
ARBs. In primary prevention, RAS blockade was most
effective in patients with LVH and/or heart failure. In
secondary prevention, RAS blockade reduced the odds
for atrial fibrillation recurrence after cardioversion by
45% (0.34–0.89, P< 0.01) and on medical therapy by
63% (0.27–0.49, P< 0.00001). However, we must remem-
ber that most of the trials included in these meta-analyses
were not designed to investigate atrial fibrillation. In a
prespecified analysis of the VALUE trial, the use of valsartan
(vs. amlodipine) was associated with a 16% reduction
(P< 0.0455) in the incidence of at least one documented
occurrence of new-onset atrial fibrillation and reduced the
incidence of persistent atrial fibrillation by 32% (P< 0.0046)
[46]. Similar findings showing the benefit of ARBs in reduc-
ing the incidence of new-onset atrial fibrillation were also
documented in prespecified analysis of data from the LIFE
study, in which the incidence of new-onset atrial fibrillation
was compared between patients treated with losartan vs.
the beta-blocker, atenolol [9]. The 2007 ESH/ESC guidelines
[64] summarize evidence from posthoc analyses of heart
failure and hypertension trials showing a lower evidence of
new-onset atrial fibrillation in patients receiving an ARB (in
one trial an ACE inhibitor). Although warning against the
possible bias of posthoc analyses, nonetheless the guide-
lines suggested ARBs and ACE inhibitors as preferred drugs
in patients with hypertension at risk for developing atrial
fibrillation. A plausible explanation for this was the associ-
ation between atrial enlargement and LVH, the favourable
effects of blockers of the RAS on both cardiac alterations,
and the relationship between LVH regression and reduction
in new-onset atrial fibrillation [65,66]. However, data accu-
mulated since then do not consistently support in all of
them this recommendation. Since then, new studies such as
the ONgoing Telmisartan Alone and in Combination With
Ramipril Global Endpoint Trial (ONTARGET), the Telmi-
sartan Randomised Assessment Study in ACE Intolerant
Subjects with Cardiovascular Disease (TRANSCEND), the
Prevention Regimen for Effectively Avoiding Second
Strokes (PROFESS) trial and the Irbesartan in Heart Failure
with Preserved Systolic Function trial were published. In
ONTARGET [67] new atrial fibrillation was just slightly less
frequent with the ARB (telmisartan) than with the ACE
inhibitor (ramipril) treatment, indicating no difference
between these two types of RAS blockade. The placebo
comparisons in the TRANSCEND [68] and the PROFESS [69]
trials, could not confirm a protective effect of ARBs against
onset of atrial fibrillation, although the absolute numbers
were low and the detection power of the analysis may have
been insufficient. The Heart Outcomes Prevention Evalu-
ation study included patients with high cardiovascular risk
without heart failure and left ventricular systolic dysfunc-
tion and randomized the patients to treatment with an ACE
inhibitor (ramipril) or placebo [70]. No statistically signifi-
cant difference in the proportion of patients who developed
atrial fibrillation was found between the ACE inhibitor and
placebo, and treatment with ACE inhibition had no pro-
tective effect on development of atrial fibrillation with anCopyright © Lippincott Williams & Wilkins. Unauth
Journal of HypertensionOR of 0.92 (0.68–1.24, P¼ 0.57). In the TRANSCEND trial
[68], patients intolerant to ACE inhibitors with cardiovas-
cular disease or diabetes with end-organ damage, were
randomized to treatment with an ARB (telmisartan) or
placebo, and no significant effect on new-onset atrial
fibrillation was found. Several relatively small prospective
randomized controlled trials have demonstrated that
therapy with ACE inhibitors or ARBs conferred an
additional benefit on risk of recurrent atrial fibrillation after
cardioversion when coadministered with antiarrhythmic
drug therapy, usually amiodarone, compared with an anti-
arrhythmic drug alone [71,72]. Meta-analyses driven by
these studies have reported a significant 45–50% reduction
in RR of recurrent atrial fibrillation [73,74]. Conversely, a
double-blind, placebo-controlled study – Candesartan in
the Prevention of Relapsing Atrial Fibrillation (CAPRAF) –
failed to demonstrate any benefit of therapy with cande-
sartan for preservation of sinus rhythm after cardioversion
in patients who did not receive antiarrhythmic drug therapy
[75]. The largest secondary prevention study, Gruppo
Italiano per lo Studio della Sopravvivenza nell’Insufficienza
cardiaca atrial fibrillation (GISSI-AF), in 1442 patients with
cardiovascular risk factors (mainly hypertension, 85%) and
paroxysmal or recently cardioverted persistent atrial fibril-
lation, demonstrated no effect of valsartan added on top of
optimal medical therapy (including antiarrhythmic drugs
and ACE inhibitors) on the primary endpoint of time to first
atrial fibrillation recurrence [heart rate (HR) 0.99; 95%
confidence interval (CI) 0.85–1.15; P¼ 0.84] or the number
of patients with more than one atrial fibrillation recurrence
(26.9 vs. 27.9%) compared with placebo at 1-year follow-up
[76]. There are different mechanisms explaining the
beneficial effects of RAS blockers in patients with hyper-
tension with atrial fibrillation. Blockade of the RAS may
prevent left atrial dilatation, atrial fibrosis, dysfunction and
slowing of conduction velocity, with some studies also
indicating direct antiarrhythmic properties. Favourable
effects of RAS blockers on cardiac alterations such as atrial
enlargement and LVH may explain the reduction in new-
onset atrial fibrillation [69,70].
Beta-blockers
The use of beta-blockers as first-line therapy for hyperten-
sion has lately been questioned, but beta-blockers are
undoubtedly effective in atrial fibrillation rate-control
during atrial fibrillation and possibly in maintaining sinus
rhythm, especially in heart failure and in cardiac postop-
erative settings [77,78]. In a systematic review including
almost 12 000 patients with systolic heart failure (about 90%
received RAS-blockade), and therefore at high risk for atrial
fibrillation, the incidence of new-onset atrial fibrillation was
significantly lower in the patients treated with beta-blockers
compared with those assigned to placebo with a RR
reduction of 27% (14–38%, P< 0.001) [78]. A history of
atrial fibrillation and systolic heart failure may be a specific
indication for using beta-blockers. Treatment with sotalol, a
nonselective beta-blocker with class III antiarrhythmic
activity, is effective in maintaining sinus rhythm after car-
dioversion, but has proarrhythmic effects and is not recom-
mended as antihypertensive treatment. In hypertension
trials like the LIFE study, the ARB-based therapy (losartan)orized reproduction of this article is prohibited.
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Box 3 Atrial fibrillation and antithrombotic treatment
1. Patients with CHADS2-VASc score 1 should receive aspirin or oral
anticoagulation treatment. However, in viewing that most patients with
hypertension are over 65 years old, of which half of them are female and
most of them have subclinical or clinical organ damage it is concluded that
they will receive anticoagulation treatment.
2. VKAs have been proven effective for more than 50 years and are the
standard anticoagulation treatment for atrial fibrillation. However, they
have disadvantages that result in substantial morbidity and mortality as well
as underutilization for different reasons.
3. New oral anticoagulants such as rivaroxaban, dabigatran and apixaban that
do not require international normalized ratio monitoring, seems to be
particularly promising according to recent studies. Rivaroxaban was
approved by the Federal Drug Association in 2010 and by the European
Medicines Evaluation Agency in 2011.
Manolis et al.was superior to beta-blocker (atenolol) in reducing the risk
of new and recurrent atrial fibrillation. However, it is also
difficult to draw conclusions from the results of trials
comparing two or more active antihypertensive treatment
regimens, due to uncertainty as to whether the observed
effects may represent a detrimental effect of one regimen or
a beneficial effect of the other. In the United Kingdom-
based General Practice Research Database, with approxi-
mately 5 million patient records, it was found that ACE
inhibitors, ARBs and beta-blockers were more effective
than calcium channel blockers (CCBs) in reducing the risk
of atrial fibrillation [79]. Possible mechanisms of action of
beta-blockers to this effect may be prevention of adverse
remodelling and ischemia reduced sympathetic drive or
counteraction of the beta-adrenergic shortening of action
potential, which otherwise could contribute to perpetu-
ation of atrial fibrillation [77,78]. However, recurrence rate
of atrial fibrillation is known to be high, even under beta-
blocker prophylaxis.
Calcium channel blockers
CCBs are a heterogeneous group of drugs with antihyper-
tensive properties. Nondihydropyridines such as diltiazem
and verapamil are used to slow the ventricular response in
atrial fibrillation, and verapamil has also been investigated
for its effectiveness in maintaining sinus rhythm after car-
dioversion. Calcium lowering drugs could hypothetically
attenuate the calcium overload in tachycardia-induced
electrical remodelling of the atria [80]. In a study by De
Simone et al. [81] additional treatment with verapamil
significantly reduced the recurrence of atrial fibrillation
within 3 months compared with propafenone alone. How-
ever, other studies have shown more disappointing results
[80–82]. In the VALUE trial the ARB valsartan was more
effective than the CCB amlodipine in preventing new-onset
atrial fibrillation [46].
In a retrospective study using a national integrated
medical and pharmacy claims database in the United States,
almost 5500 patients treated for hypertension with an ACE
inhibitor were compared to an equal number of matched
patients treated with a CCB. At about 4 years of follow-up
the incidence of new atrial fibrillation was significantly
lower in the ACE inhibitor-treated patients with a HR of
0.85 (0.74–0.97) [83]. In a nested case–control analysis
from the United Kingdom-based General Practice Research
Database, similar results were found [79]. Four thousand
six hundred and sixty-one patients with atrial fibrillation
and 18 641 matched controls from a hypertension popu-
lation were compared and the authors found that
treatments with ACE inhibitors [OR 75 (0.65–0.87)], ARBs
[OR 0.71 (0.57–0.89)] or beta-blockers (OR 0.78
(0.67–0.92)) were associated with a lower risk for atrial
fibrillation than treatment with CCBs. However, in such
observational studies, bias in treatment cannot be excluded
and blood pressure control and changes cannot be eval-
uated.
Diuretics
Diuretics are often included in antihypertensive treatment
regimens, but the effect on new-onset atrial fibrillation has to
our knowledge not been thoroughly investigated. Caution toCopyright © Lippincott Williams & Wilkins. Unaut
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therapy with Kþ wasting diuretics such as thiazides, chlorta-
lidone and indapamide is recommended.
Aldosterone antagonists
Patients with primary hyperaldosteronism have a 12-fold
higher risk of developing atrial fibrillation than theirmatched
counterpartswithessential hypertension. Increasedaldoster-
one levels have been reported in patients with atrial fibrilla-
tion. Pretreatment with spironolactone in a dog atrial
fibrillation model reduced the amount of atrial fibrosis and
inducibility of atrial fibrillation. Several trials with spirono-
lactone and eplerenone are ongoing.
ATRIAL FIBRILLATIONAND
ANTITHROMBOTIC TREATMENT
The decision to cover the topic of antithrombotic treatment
was based on the fact that in all atrial fibrillation trials the
prevalence of hypertension varies from 60 to 90%, showing
the importance of hypertension as a risk factor for the
development of atrial fibrillation [10–23] (Box 3). Hyper-
tension is part of CHADS2 [59] and CHA2DS2-VASc risk score
[60] for stroke, and according to the guidelines patients with
risk score 1 should receive oral anticoagulation treatment or
aspirin; however, oral anticoagulation treatment is pre-
ferred rather than aspirin [63]. In daily practice a large
proportion of patients with hypertension are older than
65, or are women, and since patients with hypertension
have a risk score of at least 2, the majority should receive
oral anticoagulation treatment, unless contraindicated.
Indeed, anticoagulation treatment should be given not only
to patients with persistent or permanent atrial fibrillation,
but also to those with paroxysmal atrial fibrillation, who
should be regarded as having the same risk.
For over half a century oral anticoagulation in atrial
fibrillation was limited to the use of vitamin K antagonists
(VKAs). Oral anticoagulation with VKA (with target INR
2–3) is the current guideline recommended standard of
care for stroke prevention in atrial fibrillation in moderate-
and high-risk patients (Fig. 1). VKA are highly effective
when patients are maintained at an appropriate therapeutic
range (INR 2–3) for the majority of time (60–70%). The
target intensity of anticoagulation involves a balance
between prevention of ischemic stroke and avoidance of
hemorrhagic complications, and risk/benefit ratio shouldhorized reproduction of this article is prohibited.
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Hypertension and atrial fibrillationbe estimated in each individual patient. Targeting the low-
est adequate intensity of anticoagulation to minimize the
risk of bleeding is particularly important for elderly atrial
fibrillation patients. An assessment of bleeding risk should
be part of the patient assessment before starting antico-
agulation. The use of HAS-BLEED score should be used in
order to assess the risk of bleeding in atrial fibrillation
patients [84] and a risk score at least 3 indicates a risk of
bleeding that requires caution and/or regular review, as
well as consideration of correctable risk factors for bleeding
(e.g. uncontrolled blood pressure, avoiding concomitant
aspirin and/or NSAIDs, improving INR control to avoid
‘labile INRs’, etc.). A meta-analysis of 29 trials with more
than 28 000 patients showed that adjusted-dose warfarin
results in a reduction in ischemic stroke by 64% and in all-
cause mortality by 26%. This reduction was similar for both
primary and secondary prevention and for both disabling
and nondisabling strokes. By on-treatment analysis, the
prevention efficacy of oral anticoagulation exceeded
80%. Supported by the results of the trials, treatment with
oral anticoagulation should be considered for atrial fibril-
lation patients with at least one stroke risk factors provided
there are no contraindications. Aspirin offers only modest
protection against stroke for patients with atrial fibrillation,
and in the meta-analysis by Hart et al. [85] resulted in a
nonsignificant 19% reduction in stroke and insignificant
impact on mortality. Even this 19% reduction was driven
by one single positive trial, the SPAF-I trial that used aspirin
325mg daily, with significant internal heterogeneity
between the warfarin eligible and ineligible groups, and
since the trial was stopped early, the effect size of aspirin
may have been exaggerated. In the other trials, the dose of
aspirin also differed markedly, ranging from 50 to 1300mg
daily. Nine studies compared the effects of VKAwith aspirin
and found significant reduction of primary endpoint 39% in
favour of treatment with VKA.
Recent studies have assessed the thienopyridine
antiplatelet agent clopidogrel with aspirin for stroke pre-
vention in atrial fibrillation. The atrial fibrillation Clopi-
dogrel Trial with Irbesartan for the prevention of Vascular
Events-Warfarin arm trial (ACTIVE-W), compared clopi-
dogrel plus aspirin with oral anticoagulation therapy
with warfarin for prevention of vascular events in atrial
fibrillation with an average of two stroke risk factors.
Anticoagulation therapy was superior to the combination
of clopidogrel plus aspirin (RR reduction 40%) with no
differences in bleeding events between treatment arms
[86]. The aspirin arm (ACTIVE A) trial assessed whether
the addition of clopidogrel to aspirin would reduce the
risk of vascular events in atrial fibrillation patients who
were considered unsuitable for therapy with oral anti-
coagulation with warfarin. It was found that major vascular
events are reduced by 11% in patients receiving the com-
bination aspirin–clopidogrel vs. aspirin alone, and the
reduction was primarily due to a reduction in the rate of
stroke with clopidogrel [87]. However, it was reported an
increased risk of major haemorrhages in patients receiving
aspirin plus clopidogrel vs. those receiving aspirin plus
placebo.
Although millions of patients have benefited from
drugs like warfarin, these agents come with a large list ofCopyright © Lippincott Williams & Wilkins. Unauth
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morbidity as well as underutilization of anticoagulation,
particularly in the elderly, for whom numerous concomitant
medications are typically prescribed. Underuse of oral anti-
coagulants for high-risk atrial fibrillation patients was found
in most of the 54 studies (1998–2008) reporting both patient
stroke risk and patients treated. Over two-thirds of studies of
atrial fibrillation patients with prior stroke or transient ische-
mic attack reported treatment levels of under 60% of eligible
patients. Most studies based on CHADS2 score reported oral
anticoagulant treatment levels of high-risk individuals below
70% [88].
Aiming to avoid these problems, the pharmaceutical
industry has recently succeeded in developing novel oral
anticoagulants that are likely to change the approach to
anticoagulation dramatically.
NEWAND INVESTIGATIONAL
ANTITHROMBOTIC AGENTS
The new oral anticoagulants fall into two broad categories:
the oral direct thrombin inhibitors (e.g. dabigatran, xime-
lagatran) and the oral factor Xa inhibitors (e.g. rivaroxaban,
apixaban, edoxaban). Different trials were published or are
under investigation in this new area such as RELY, the
stroke prevention using an oral thrombin inhibitor in atrial
fibrillation (SPORTIF) trial, ROCKET-AF, AVERROES, the
Apixaban for Reduction In STroke and Other Thromboem-
boLic Events in atrial fibrillation (ARISTOTLE) trial, and the
Effective aNticoaGulation with factor xA next GEneration in
Atrial Fibrillation-Thrombolysis In Myocardial Infarction
study 48 trial (Table 3).
RELY trial
Dabigatran was evaluated in a large, open-label, random-
ized trial (RELY) in which it was compared with warfarin
(goal INR 2.0–3.0) in 18 113 patients with nonvalvular atrial
fibrillation [20]. Eligible participants had at least one risk
factor. Two doses of dabigatran (110 and 150mg twice
daily) were evaluated. The mean age of participants was 71
years, 63.6% were male, half had prior long-term therapy
with VKAs, and the mean CHADS2 risk prediction score was
2.1. The primary outcome was all stroke (ischemic or
hemorrhagic) or systemic embolism. The 150mg twice
daily dabigatran treatment was superior to warfarin treat-
ment. The primary outcome of stroke or systemic embolism
occurred in 1.71% of patients per year in thewarfarin group,
in 1.54% of patients per year in the 110mg twice daily
dabigatran group (P¼ 0.34), and in 1.11% of patients per
year in the 150mg twice daily dabigatran group (P< 0.001),
respectively. The rate of major bleeding was 3.57% per year
in patients treated with warfarin, 2.87% per year in patients
treated with 110mg b.i.d. [bis in die (twice a day)] dabiga-
tran (P¼ 0.003) and 3.32% in patients treated with 150mg
twice daily dabigatran (P¼ 0.31) [89]. The rate of haemor-
rhagic stroke was reduced with both doses of dabigatran
compared to warfarin treatment (0.12% per year with
110mg and 0.10% per year with 150mg vs. 0.38% with
warfarin, P< 0.001). Warfarin needs to be monitored by
determining the INR, but dabigatran does not require
monitoring. Recent group analysis of the RELY trial foundorized reproduction of this article is prohibited.
www.jhypertension.com 247
TABLE 3. Trials with new oral anticoagulants
Trial RELY ROCKET-AF ARISTOTLE
Drug used Dabigatran vs. warfarin Rivaroxaban vs. warfarin Apixaban vs. warfarin
Dose 150 or 110mg b.i.d. 20 or 15mg QD 5mg b.i.d.
vs warfarin (INR 2–3) vs warfarin (INR 2–3) Vs warfarin (INR 2–3)
Number of patients 18 113 14000 18201
Mean age (years) 71.5 73 70
Percentage of hypertension 80 90 85
Mean CHADS2 Score 2.1 2.1 2.1
Conclusions Dabigatran 110mg noninferior to warfarin,
with 20% less major bleedings
Rivaroxaban noninferior to warfarin
on intention to treat analysis but
superior in on treatment analysis
Apixaban was superior to warfarin
in the risk of stroke or systemic
embolism, bleeding and all-cause
mortality
Dabigatran 150mg superior to warfarin with
similar rate of major bleedings
Similar rate of major bleedings
Approval FDA FDA-EMA: under consideration
Doses of 150 and 75mg (if CrCl 15–30ml/min)
EMA: positive opinion
b.i.d.bis in die (twice a day); CHADS, Congestive heart failure, Hypertension, Age, Diabetes, Stroke; FDA, Federal Drug Association; INR, international normalized ratio.
Manolis et al.no significant interactions between the time within the
therapeutic range with warfarin treatment and both doses
of dabigatran, thereby confirming the benefit of the 150mg
twice daily dose of dabigatran at reducing stroke independ-
ent of the quality of warfarin treatment [90]. Another sub-
group analysis of patients with prior stroke or transient
ischaemic attack showed noninferiority of both doses of
dabigatran compared with warfarin in preventing stroke
but did not show superiority of dabigatran in this subgroup
of patients with CHADS2 score of at least 3 [91]. Myocardial
infarction was numerically (but not statistically) more fre-
quent with dabigatran and occurred at rates of 0.82% (RR
1.29; 95% CI 0.96–1.75; P¼ 0.09) and 0.81% (RR 1.27; 95%
CI 0.94–1.71; P¼ 0.12) with dabigatran, 110mg and 150mg
twice daily, respectively, and 0.64% with warfarin. There is
no specific antidote for dabigatran, which has a half-life of
12–17 h. Supportive therapy for severe haemorrhage may
include transfusions of fresh frozen plasma, packed red
blood cells, haemodialysis or surgical intervention if
appropriate. Dabigatran etexilate was approved by the
Federal Drug Association (FDA) on 19 October 2010, for
marketing in the United States for the prevention of stroke
and systemic embolism in patients with non valvular atrial
fibrillation. A dose of 150mg twice daily was approved for
patients with a creatinine clearance higher than 30ml/min,
whereas in patients with severe renal insufficiency (crea-
tinine clearance 15–30ml/min) the approved dose is 75mg
twice daily, a dose currently marketed in the European
Union but not evaluated in the RELY trial. Recently the
European Medicines Evaluation Agency also approved
dabigatran in Europe. Thus, dabigatran is the first new oral
anticoagulant to become available for clinical use in more
than 50 years.
SPORTIF trials
Two long-term phase III studies compared ximelagatran
with warfarin in patients with atrial fibrillation [92,93].
Despite evidence of efficacy comparable to warfarin and
some advantages in terms of bleeding risk, ximelagatran
development was abandoned, mainly because of concerns
about hepatic toxicity.Copyright © Lippincott Williams & Wilkins. Unaut
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A total of 14 264 patients with atrial fibrillation were
randomized in a double-blind, double dummy manner to
receive either the factor Xa inhibitor rivaroxaban 20mg
once daily (15mg if creatinine clearance was between 30
and 49ml/min) or dose-adjusted warfarin (INR 2.0–3.0).
Inclusion criteria were documented atrial fibrillation within
6 months prior randomization and at least two risk factors
[21]. Patients with CHADS2 score of at least 2 were enrolled
but only 13% of all patients had a CHADS2 score of 2,
whereas all other patients (87% of all) enrolled in ROCKET
atrial fibrillation had a CHADS2 score of at least 3. The
primary endpoint of stroke and noncerebral embolism
occurred in 2.12% per year of patients treated with rivar-
oxaban and in 2.42% of patients treated with warfarin
(P¼ 0.117). Overall, rivaroxaban was noninferior to war-
farin in terms of the primary end point, and as noted, was
superior to warfarin in patients who remained on treatment
over the course of the 40-month trial. Rivaroxaban was not
superior to warfarin in the more conservative and conven-
tional intention-to-treat analysis. Major bleeding occurred
in 3.6% of patients in the rivaroxaban group vs. 3.45% in the
warfarin-treated group (P¼ 0.576). The rate of intracranial
haemorrhage was significantly lower with rivaroxaban
treatment compared to warfarin treatment (0.49 vs.
0.74%, P¼ 0.019). In the ROCKET-AF trial there was no
significant difference in myocardial infarction between
rivaroxaban and warfarin.
AVERROES
The AVERROES trial was a double-blind, randomized com-
parison of the oral factor Xa inhibitor apixaban vs. aspirin
for stroke prevention in patients with atrial fibrillation who
were not suitable for oral anticoagulation with a VKA.
Patients were randomized to receive either apixaban
5mg twice daily or aspirin (81–324mg daily). Five thou-
sand and six hundred patients were enrolled in AVERROES,
and the study was terminated early after an interim analysis
revealed a more than 55% reduction in the primary end-
point of stroke or systemic embolism in patients treated
with apixaban compared to patients receiving aspirin, overhorized reproduction of this article is prohibited.
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onstrated that 39.5% of randomized patients had received
prior oral VKA and 60.5% had not. A total of 72% of all
randomized patients had a CHADS2 score of 2 or less
and 28% had a score of at least 3. The primary endpoint
of stroke and systemic embolism occurred in 3.9% per year
of aspirin-treated patients vs. 1.7% per year of apixaban-
treated patients (P< 0.001). The rate of major bleeding was
1.2% for aspirin and 1.4% for apixaban (P¼ 0.33). There
was no significant difference in haemorrhagic stroke with a
rate of 0.2% per year in both treatment groups. Also, aspirin
was significantly less well tolerated compared to apixaban
[22]. Thus, in patients who fail VKA or refuse VKA, aspirin is
clearly an inferior drug for stroke prevention, it is not safer
in terms of major haemorrhage or intracranial bleeding and
is less well tolerated than the oral anticoagulant apixaban.
The positive results with apixaban for atrial fibrillation
in AVERROES come on the heels of disappointing recent
top-line results of a Phase 3 trial testing this agent in high-
risk patients with recent acute coronary syndrome. The
APPRAISE-2 (Apixaban for Prevention of Acute Ischemic
Events) study was stopped November 2010, when it
became clear that the increase in bleeding risk in patients
randomly assigned to apixaban would not be offset by a
reduction in ischemic events. The ARISTOTLE trial rando-
mized 18 201 atrial fibrillation patients to apixaban (5mg
orally twice daily) or warfarin (target INR 2.0–3.0). After a
median follow-up of 1.8 years, results showed that apix-
aban was associated with a 21% reduction in the risk of
stroke or systemic embolism, a 31% reduction in bleeding,
and an 11% reduction in all-cause mortality. Apixaban was
superior to warfarin in preventing stroke or systolic embo-
lism (the primary end point) and was also associated with
less bleeding and lower mortality than warfarin [94].
WHAT DOCURRENTGUIDELINES
RECOMMEND FORTHE NEW
ANTITHROMBOTIC DRUGS?
The ESC guidelines for the management of atrial fibrillation
[57]: There was no formal recommendation for the use of
dabigatran, because at the time of the publication there was
no approval for the drug in Europe. However, the guide-
lines did include the results of the RELY trial and text on
how to use dabigatran 110 and 150mg b.i.d. in relation to
stroke risk (CHA2DS2-VASc) and bleeding risk (HAS-BLED)
[57].
An American Heart Association/American Stroke Associ-
ation stroke guideline [95] did not include any formal
recommendation for the use of new anticoagulants as
approval was not available at the time of writing.
The Canadian Cardiovascular Society guidelines give a
conditional recommendation of high quality of evidence
suggesting that when oral anticoagulation is indicated most
patients should receive dabigatran in preference to warfarin
[96].
American College of Cardiology Foundation/American
Heart Association/Heart Rhythm Society focussed update
[97,98] gave dabigatran a class I recommendation for atrial
fibrillation patients as follows: ‘dabigatran is useful as an
alternative to warfarin for the prevention of stroke andCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensionsystemic thromboembolism in patients with paroxysmal to
permanent atrial fibrillation and risk factors for stroke or
systemic embolization, who do not have a prosthetic
heart valve or haemodynamically significant valve disease,
severe renal failure (creatinine clearance< 15ml/min) or
advanced liver disease (impaired baseline clotting func-
tion)’ (Level of Evidence B). However, the cost of the drug is
an important issue, and it is also important to select the
candidates for the use of the above new drugs in order for
the therapy to be cost effective. Nevertheless, the cost of
regular INR monitoring should also be taken into account.
Regarding some practical aspects on the use of dabiga-
tran: When switching from warfarin to dabigatran, the latter
has to be started when after stopping warfarin, INR falls
below 2.0. When there is need to switch again to warfarin
and renal and renal function is normal (i.e. CrCl> 50ml/
min), warfarin is started along with dabigatran and the latter
is stopped after 3 days of concomitant administration.
When renal function is impaired (CrCl¼ 30–50ml/min)
dabigatran should be stopped on day 0 and warfarin be
started on day 1. In case of an elective surgical procedure
and when renal function is normal (i.e. CrCl> 50ml/min)
the procedure can be undertaken after skipping 2 doses of
dabigatran (i.e. 24 h). When renal function is impaired
(CrCl¼ 30–50ml/min) dabigatran has to be stopped
3–5 days before the elective procedure. Six hours after
restarting dabigatran there is maximal anticoagulant effect
of the drug.
Some patients on dabigatran have dyspeptic complaints.
They should take the medicine with water or food. The use
of proton pump inhibitors can be very helpful.
CONCLUSION
Patients with hypertension suffer from an increased risk of
atrial fibrillation and hypertension is the most common
disorder in atrial fibrillation trials. Awareness of the
increased risk of atrial fibrillation in patients with hyperten-
sion may require closer follow-up as atrial fibrillation has a
significant effect on cardiovascular outcome. Atrial fibrilla-
tion is usually a progressive disease that often worsens over
time (’atrial fibrillation begets atrial fibrillation’) and this
worsening is driven by electrical, contractile and structural
changes in the atria, known as atrial remodelling. Atrial
fibrillation leads to reduced cardiac function and increased
risk of thromboembolism. Prevention and new treatment
regimens of atrial fibrillation are needed, considering
the increasing elderly population, the high percentage of
uncontrolled hypertension, the risk of stroke and the
worsening of other comorbidities in the presence of atrial
fibrillation.
Management of atrial fibrillation includes antihyperten-
sive, antiarrhythmic and antithrombotic drugs. Prevention
of atrial fibrillation with antihypertensive drugs such as ACE
inhibitors, ARBs and beta-blockers has been shown to be
more effective than other classes mainly in postmyocardial
infarction and heart failure trials and in other high-risk
patients with hypertension including those with LVH by
ECG. Antithrombotic treatment is very effective in the
prevention of stroke and new oral antithrombotics that
do not require INR monitoring seem to be particularlyorized reproduction of this article is prohibited.
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Manolis et al.promising drugs according to recently published trials
and guidelines.
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